Showing 1 - 5 results of 5 for search 'Fajun Xie', query time: 0.03s Refine Results
  1. 1
    L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment

    L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment by Meihui Li, Jing Qin, Fajun Xie, Lei Gong, Na Han, Hongyang Lu

    Published 2022-08-01
    Get full text
    Article
  2. 2
    Bone metastasis in non-small-cell lung cancer: genomic characterization and exploration of potential targets

    Bone metastasis in non-small-cell lung cancer: genomic characterization and exploration of potential targets by Jiali Gong, Shumin Hu, Qianyun Shan, Jing Qin, Na Han, Fajun Xie, Hongyang Lu

    Published 2024-03-01
    Get full text
    Article
  3. 3
    Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer

    Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer by Hongyang Lu PhD, Jing Qin PhD, Na Han MD, Fajun Xie PhD, Lei Gong MD, Chenghui Li MD

    Published 2018-12-01
    Get full text
    Article
  4. 4
    Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

    Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐... by Kaiyan Chen, Yanjun Xu, Zhiyu Huang, Xiaoqing Yu, Wei Hong, Hui Li, Xiaoling Xu, Hongyang Lu, Fajun Xie, Jun Chen, Youzu Xu, Yun Fan

    Published 2023-10-01
    Get full text
    Article
  5. 5
    A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti–PD-1 mAb, in patients with advanced or metastatic solid tumors

    A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL... by Zhiyu Huang, Yanjun Xu, Wei Hong, Lei Gong, Kaiyan Chen, Jing Qin, Fajun Xie, Feng Wang, Xin Tian, Xiangrui Meng, Wenlei Feng, Lingyan Li, Baihui Zhang, Xiaoyan Kang, Yun Fan

    Published 2023-10-01
    Get full text
    Article

Search Tools: